Factor V polyclonal, anti-human

Quantity: 200 µl

Background:
The defined antibody reactivity is restricted to Factor V, its activated form (Fva) and degradation products. In immunoelectrophoresis, bidimensional electrophoresis, and double radial immunodiffusion (Ouchterlony) against plasma, a single precipitin line is obtained which shows a reaction of identity with the precipitated purified Factor V. No precipitation is obtained with Factor V-depleted plasma and serum. In precipitating techniques as electroimmunodiffusion, immunoelectrophoresis, single and double radial immunodiffusion (Mancini, Ouchterlony), bidimensional electrophoresis and neutralization assay. The presence of non-precipitating antibodies has not been assayed. If used in more sensitive test procedures or as catching or detection antibody in solid phase immunoassays specificity controls should always be include. Plasma samples and all assay components must contain EDTA to stabilize the proteins.

Isotype: Rabbit Polyclonal

Source: Plasma factor V is a relatively labile glycoprotein (MW 350,000) which is essential for normal clotting and haemostasis. It is synthesized in hepatocytes and reticuloendothelial cells in the liver. Factor V is present in platelet alpha-granules but not on the surface of the intact platelet. It is released following platelet aggregation and its coagulant activity is distinguishable from plasma factor V. Thrombin activates Factor V to FVa by proteolysis resulting in the release of several polypeptides with molecular weight of 70,000 to 150,000. After clotting he protein is no longer detectable in the serum. FVa binds to receptor sites in the platelet membrane which protects Fva from the action of inhibitors (e.g. protein C). The concentration of factor V in adult plasma is 1-3 ?g/ml. Newborn infants have similar levels. Factor V deficiency is associated with severe haemorrhagic disorder. Congenital deficiency with an autosomal bleeding is relatively rare. It exists in two molecular forms: coagulant activity may be reduced together with factor V antigen levels (impaired synthesis), or low coagulant activity is associated with the presence of a variable level of plasma factor V (abnormal molecules). Both conditions lead to frequent minor bleedings of skin and mucosal tissues. Acquired deficiency with reduced factor V antigen levels can be a reliable parameter of liver damage in severe liver diseases. Circulating antibodies to factor V acting as neutralizing inhibitors of plasma an platelet factor V have been described. Highly purified Factor V is isolated from pooled human plasma and used for immunization. Freund's complete adjuvant is used in the first step of the immunization procedure.

Form: Delipidated, heat inactivated, in PBS and 0.1% sodium azide.

Reactivity: human

Cross Reactivity:
The antiserum does not cross react with any other component of Human plasma. Inter-species crossreactivity is a normal feature of antibodies to plasma proteins since they frequently share antigenic determinants. Cross-reactivity of this antiserum has not been tested in detail.

Applications: Immunoprecipitation

Storage: Store at 4C, or in small aliquots at -20C.